
FDA Approves Dupilumab as First New Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 and older, marking the first new targeted therapy for the condition in more than ten years, according …